Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intraoperative Methadone in Orthopedic Surgery
NCT05831345Phase 3
Key facts
- Status
- Recruiting
- Start
- Feb 2023
- Primary completion
- Dec 2025
- Countries
- 1
- Sponsor
- CHU Brugmann
- Modality
- Orthosteric Ligands
- Drugs
- methadone
- Conditions
- postoperative pain
01
Overview
Phase 3, randomised, double-blind trial of methadone in postoperative pain, sponsored by CHU Brugmann. Primary endpoints: Total morphine consumption at 72 hours and Visual Analogue Scale at 24 hours. Started Feb 2023; status: recruiting.
02
Design
- Study design
- RandomizedDouble-blind
03
Who it enrols
Patients undergoing elective partial or total hip and knee arthroplasty. Excludes patients with renal failure (GFR < 90), significant hepatic dysfunction, known heart failure, or history of opioid abuse.
04
Endpoints
Primary
Total morphine consumption
Visual Analogue Scale
Secondary
Patient satisfaction
Beyond the preview
Go deeper on NCT05831345.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05831345.